Nutraceuticals target androgen receptor-splice variants (AR-SV) to manage castration resistant prostate cancer (CRPC)

Update your browser to view ScienceDirect.

Request details:

Request ID: 8dd5e23f8db97aee-LAX
IP: 116.62.10.13
UTC time: 2024-11-04T16:12:07+00:00
Browser: Mozilla/5.0 (X11; U; Linux x86_64; en-US; rv:1.9.1.4) Gecko/20091030 Gentoo Firefox/3.5.4